Triamcinolone
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
- Triamcinolone
- Pharmacist Assessment Report
- Triamcinolone: From Autoimmune and Endocrine Conditions to Alopecia Mucinosa
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Triamcinolone: From Autoimmune and Endocrine Conditions to Alopecia Mucinosa
One-Sentence Summary
Triamcinolone is a corticosteroid, originally used for autoimmune and inflammatory diseases, adrenal insufficiency, Crohn disease and certain leukaemias. The TxGNN model predicts it may be effective for alopecia mucinosa (follicular mucinosis), but there are no registered clinical trials and only 2 case-report publications, neither of which directly evaluates triamcinolone. This is a model prediction with very limited supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Autoimmune disease, adrenocortical insufficiency, Crohn disease / inflammatory bowel disease, acute lymphoblastic leukaemia and others (the approved indication text in the India licence records is blank) |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 (model prediction with no clinical trials; only case reports available) |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, triamcinolone is a synthetic glucocorticoid, its efficacy in inflammatory and autoimmune conditions is established, and mechanistically it may be applicable to inflammatory skin conditions.
Follicular mucinosis involves inflammatory cell infiltration around hair follicles together with mucin deposition. Corticosteroids, including intralesional or topical triamcinolone, have an anti-inflammatory rationale and are used in clinical practice for inflammatory scalp and hair disorders. That is the plausible link between the original indications (inflammatory and autoimmune diseases) and this prediction.
However, the retrieved literature consists only of case reports and does not directly assess triamcinolone. The very high TxGNN score is a computational prediction, not evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23968145 | 2014 | Case report | Int J Dermatol | Topical bexarotene 1% gel successfully treated persistent idiopathic follicular mucinosis; no uniformly effective therapy exists. Does not involve triamcinolone. |
| 14170262 | 1964 | Case report | Hifuka kiyo. Acta dermatologica | Case of alopecia mucinosa (Pinkus type / follicular mucinosis). No abstract available; triamcinolone-specific findings cannot be confirmed. |
India Market Information
Triamcinolone has 20 valid single-ingredient registrations and none cancelled. The approved indication text is blank in the records. Five main registrations are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 116709 | Kenatroy 40mg Injection (Troikaa Pharmaceuticals) | Vial of 1 ml injection | Not stated |
| 118970 | Kencort 16mg Tablet (Kenn Pharmaceuticals) | Strip of 10 tablets | Not stated |
| 108521 | Injicort 40mg Injection (Zydus Healthcare) | Vial of 1 injection | Not stated |
| 122892 | Lupicort 40mg Injection (Lupin) | Vial of 1 ml injection | Not stated |
| 8152 | Amecort 4mg Tablet (Ikon Remedies) | Strip of 10 tablets | Not stated |
Available forms include injectable (vials) and oral (tablets).
Safety Considerations
- Contraindication signals from the knowledge graph (not label text): hypertension, congestive heart failure, epilepsy, liver disease, gallbladder disease, hyperglycaemia, measles, herpes simplex keratitis, and several pituitary deficiency and hypogonadotropic hypogonadism conditions (including Kallmann syndrome and Sheehan syndrome).
- Drug interactions: 696 interactions were identified. Examples:
- Major: adalimumab
- Moderate: zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, nifedipine, ibuprofen, ethinylestradiol, butalbital, albiglutide, aldesleukin, alefacept, alemtuzumab, aliskiren, tetanus toxoid vaccine
- Minor: formoterol, salbutamol
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no clinical trials, and the only two publications are old or unrelated case reports (one on a different drug), so there is no triamcinolone-specific efficacy data in alopecia mucinosa. Label-based safety data is also missing.
To proceed, the following is needed:
- Triamcinolone-specific clinical data in follicular mucinosis (case series or controlled studies)
- Detailed mechanism of action data
- Package insert warnings and contraindications from the India licence documents, which are needed for safety screening
- Approved indication text for the registered products, to clarify the current label scope
- Route and formulation compatibility assessment (intralesional or topical use versus the registered injectable and oral forms)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.